|Author (Corporate)||Cardiff EDC|
Information and reports on the development of a vaccine to tackle the COVID-19 (coronavirus) pandemic by the pharmaceutical companies Sanofi and GlaxoSmithKline (GSK).
Sanofi and GSK announced on 14 April 2020 they had signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies.
The joint venture announced on 29 July 2020 they had agreed to supply the United Kingdom with up to 60 million doses of the potential vaccine. This was followed by an announcement by the European Commission on 31 July that exploratory talks had been concluded with Sanofi-GSK to also purchase the potential vaccine, in the context of its EU Strategy for COVID-19 vaccines. The contractual framework would be in place for the purchase of 300 million doses on behalf of the European Union's Member States, once a vaccine was proven to be safe and effective against the virus. An agreement was also reached with the United States for the provision of a vaccine.
|Subject Tags||Medicines | Medical Devices|
|International Organisations||European Union [EU]|